GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...

GSK reports positive results from B-Well 1 & B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B: London, UK Thursday, January ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

Please provide your email address to receive an email when new articles are posted on . HBV-infected children treated with combination PEG-INF a-2b/nucleos(t)ide analogues achieved higher HBsAg loss ...

Hepatitis B virus is often silently undiagnosed, with only 10.5% of all people estimated to be living with Hepatitis B aware of their condition. Abbott has launched the HBsAg Next Qualitative Assay ...

Hepatitis B is a viral infection that impacts the liver. To test for hepatitis B, a doctor can perform a blood test that detects hepatitis B surface antigens. A positive result indicates a hepatitis B ...

Hepatitis B virus (HBV), a partially double-stranded hepatotropic DNA virus, is the aetiological agent (Box 1; Fig. 1) of acute and chronic hepatitis B in humans. In countries where HBV prevalence is ...

Reports of successful antiviral therapy for chronic hepatitis B virus (HBV) infection appeared three decades ago, 1 and during the past decade, progress has accelerated dramatically. Along with ...